Welcome to our dedicated page for BIOC news (Ticker: BIOC), a resource for investors and traders seeking the latest updates and insights on BIOC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOC's position in the market.
Biocept, Inc. (Nasdaq: BIOC) will announce its financial results for Q1 2021 on May 12, 2021, after market close. A conference call will take place at 4:30 p.m. ET to discuss the results. Participants can pre-register for immediate access. Biocept specializes in molecular diagnostic assays for cancer treatment and monitoring, including its CNSide™ assay for detecting cancer in the central nervous system. The company is also conducting COVID-19 RT-PCR testing to aid public health efforts.
Biocept, Inc. (Nasdaq: BIOC) has partnered with the Foundation for California Community Colleges to offer COVID-19 testing for the state's 116 community colleges, impacting over 2.1 million students. This initiative enables colleges to purchase Biocept's PCR-based tests through the CollegeBuys program. The tests are provided via Biocept's CLIA-certified laboratory, with results typically available within 48 hours. This partnership aims to enhance campus safety as colleges prepare for a return to in-person instruction amid the ongoing pandemic.
Biocept (Nasdaq: BIOC) has announced the full commercial launch of CNSide™, a cerebrospinal fluid assay aimed at diagnosing and managing metastatic cancers affecting the central nervous system. This assay improves detection and monitoring, addressing a significant clinical need where standard cytology falls short. Initial acceptance by neuro-oncology institutions has been positive, with a potential market exceeding $1 billion annually in the U.S. The CNSide assay shows an 80% detection rate for tumor cells, surpassing the 50% rate of traditional methods.
Biocept, Inc. (Nasdaq: BIOC) has processed over 350,000 SARS-CoV-2 samples since launching COVID-19 testing in June 2020, utilizing its RT-PCR technology at its San Diego laboratory. The company emphasizes its commitment to community health through rapid testing results while also focusing on its core oncology services, particularly its CNSide™ neuro-oncology offerings for advanced cancer patients. Biocept aims to provide actionable diagnostic information, leveraging its patented Target Selector™ technology for effective cancer treatment.
Biocept, Inc. (Nasdaq: BIOC) is hosting a webinar on April 8, 2021, focusing on its proprietary cerebrospinal fluid (CSF) assay for diagnosing central nervous system tumors. The CSF assay offers superior sensitivity over traditional CSF cytology and identifies actionable molecular targets for treatment decisions. Key speakers include prominent neuro-oncologists Amir Azadi, Nicholas Blondin, and Priya U. Kumthekar.
Participants can register for the 12:00 p.m. ET (9:00 a.m. PT) event here.
Biocept, a provider of molecular diagnostic assays, announced the grant of inducement stock options for 49,040 shares to eight new employees, effective March 31, 2021. These options, priced at $5.09 per share, are non-qualified and will vest over four years. The grant adheres to Nasdaq Listing Rule 5635(c)(4), aiming to attract talent crucial for the company's growth. Biocept specializes in liquid biopsy assays and is developing a cerebrospinal fluid assay for metastatic cancer detection, enhancing its portfolio in molecular diagnostics.
Biocept, Inc. (Nasdaq: BIOC) will host a webinar on April 8, 2021, featuring leading neuro-oncologists discussing its proprietary cerebrospinal fluid (CSF) assay. This assay aims to improve the diagnosis and management of tumors metastasizing to the central nervous system, showing enhanced sensitivity compared to the current standard, CSF cytology. The company anticipates significant interest and has estimated the market opportunity for brain metastasis diagnostics at over $1 billion annually, addressing a critical unmet clinical need.
Biocept, Inc. (Nasdaq: BIOC) reported a significant financial turnaround, achieving revenues of $18.5 million in Q4 2020, compared to $1.8 million in Q4 2019, marking its first profitable quarter with a net income of $1.9 million or $0.14 per diluted share. The surge in revenue was primarily attributed to COVID-19 testing, with approximately 140,000 samples processed. The company is focusing on its neuro-oncology strategy and has plans for a pivotal clinical trial to validate their cerebrospinal fluid assay.
Biocept, Inc. (Nasdaq: BIOC) will release its financial results for the fiscal year ended December 31, 2020, on March 29, 2021, after market hours. A conference call will follow at 4:30 p.m. ET to discuss these results and address investor inquiries. Participants can pre-register for the call or dial in using provided numbers for U.S., Canadian, and international callers. Biocept specializes in molecular diagnostic assays for cancer treatment and monitoring, including blood-based and cerebrospinal fluid assays.
Biocept, Inc. (Nasdaq: BIOC) announces participation in three virtual investment conferences in March 2021. CEO Michael Nall will engage at the H.C. Wainwright Global Life Sciences Virtual Conference on March 9-10, the 33rd Annual Roth Conference from March 15-17, and the Maxim 2021 Emerging Growth Virtual Conference on March 17-19. Biocept aims to advance its neuro-oncology initiative while maintaining its COVID-19 RT-PCR testing efforts, having processed over 300,000 samples since June 2020. The company is expanding its testing portfolio in collaboration with Aegea Biotechnologies.